A retrospective study to assess number of patients with major and life-threatening bleeds under therapy with apixaban or rivaroxaban in Germany and to analyze associated outcomes
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Nov 2020 New trial record
- 19 Nov 2020 Results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research